路透9月4日 - ** 澳大利亚Curvebeam AI公司CVB.AX股价下跌10.7%，报0.125澳元。
** Bell Potter分析师将这家医疗设备制造商的目标股价从0.18澳元下调至0.15澳元；将建议评级从 "买入 "下调至 "持有
** Bell Potter下调了Co公司26财年的收入预期，使其与25财年的业绩保持一致。 (link)
** 券商称Curvebeam AI的HiRise扫描仪的销售仍将受到限制，因为该产品尚未通过与史赛克SYK.N的Mako机器人手术系统配套使用的验证。
** Bell Potter说："我们曾预计HiRise将在26财年第四季度完成史赛克的验证，但目前还不能保证在本财年内完成。
** CVB 最后下跌 7.1%，使年度亏损达到 3.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.